The Richmond Club: Resverlogix Investor Presentation

The Richmond Club recent released an Investor Presentation highlighting Resverlogix Corp. (TSX:RVX).  Resverlogix Corp. is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials.
Watch the full video presentation